Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. Issue 12 (26th April 2021)

• Record Type: Journal Article
• Authors: Burke, Bridget Teevan; Latimer, Caitlin; Keene, C. Dirk; Sonnen, Joshua A.; McCormick, Wayne; Bowen, James D.; McCurry, Susan M.; Larson, Eric B.; Crane, Paul K.
• Is Part Of: Alzheimer's & dementia. Volume 17:Issue 12(2021)
• Page Start: 1879
• Page End: 1891
• Publication Date: 2021-04-26
• Subjects: Alzheimer's disease -- amyloid beta -- biomarkers -- cost -- dementia -- neurodegeneration -- screening -- secondary prevention -- tau; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12348
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: The AT(N) research framework categorizes eight biomarker profiles using amyloid (A), tauopathy (T), and neurodegeneration (N), regardless of dementia status. We evaluated associations with dementia risk in a community‐based cohort by approximating AT(N) profiles using autopsy‐based neuropathology correlates, and considered cost implications for clinical trials for secondary prevention of dementia based on AT(N) profiles. We used Consortium to Establish a Registry for Alzheimer's Disease (moderate/frequent) to approximate A+, Braak stage (IV‐VI) for T+, and temporal pole lateral ventricular dilation for (N)+. Outcomes included dementia prevalence at death and incidence in the last 5 years of life. A+T+(N)+ was the most common profile (31%). Dementia prevalence ranged from 14% (A–T–[N]–) to 79% (A+T+[N]+). Between 8% (A+T–[N]–) and 68% (A+T+[N]–) of decedents developed incident dementia in the last 5 years of life. Clinical trials would incur substantial expense to characterize AT(N). Many people with biomarker‐defined preclinical Alzheimer's disease will never develop clinical dementia during life, highlighting resilience to clinical expression of AD neuropathologic changes and the need for improved tools for prediction beyond current AT(N) biomarkers.